UMIN ID: UMIN000001343
Registered date:01/09/2008
Prospective study of high dose MTX with R-CHOP therapy for primary central nervous system lymphoma.
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Primary CNS lymphoma (CD20+ diffuse large B-cell lymphoma) |
| Date of first enrollment | 2007/11/01 |
| Target sample size | 10 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | 6 courses of MR-CHOP therapy: high dose MTX (2g/m2) with standard dose R-CHOP. HDC/AHST if possible. |
Outcome(s)
| Primary Outcome | Overall survival, CR rate |
|---|---|
| Secondary Outcome | Adverse events |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 80years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1, extra-CNS lesion 2, severe infectious disease 3, pre-treatment history for lymphoma 4, HIV+, HTLV1+, HBs-Ag+ 5, physician's decision of inappropriateness |
Related Information
| Primary Sponsor | Hematology and Immunology, Kanazawa Medical University |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Hematology and Immunology, Kanazawa Medical University |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Yasufumi Masaki |
| Address | 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa Japan |
| Telephone | 076-286-3511 |
| yasum@kanazawa-med.ac.jp | |
| Affiliation | Kanazawa Medical University Hematology and Immunology |
| scientific contact | |
| Name | Yasufumi Masaki |
| Address | 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa Japan |
| Telephone | 076-286-3511 |
| Affiliation | Kanazawa Medical University Hematology and Immunology |